NasdaqCM:ENLV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Enlivex Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ENLV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.1%

ENLV

0.07%

US Biotechs

2.9%

US Market


1 Year Return

-53.6%

ENLV

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: ENLV underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: ENLV underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

ENLVIndustryMarket
7 Day2.1%0.07%2.9%
30 Day-0.9%4.8%10.6%
90 Day-7.8%10.5%5.1%
1 Year-53.6%-53.6%25.1%23.9%11.4%8.9%
3 Yearn/a32.9%28.5%34.3%25.4%
5 Yearn/a-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is Enlivex Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Enlivex Therapeutics undervalued compared to its fair value and its price relative to the market?

2.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENLV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENLV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENLV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ENLV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENLV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENLV is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Enlivex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

30.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enlivex Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Enlivex Therapeutics performed over the past 5 years?

-32.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENLV is currently unprofitable.

Growing Profit Margin: ENLV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENLV is unprofitable, and losses have increased over the past 5 years at a rate of -32.8% per year.

Accelerating Growth: Unable to compare ENLV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENLV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ENLV has a negative Return on Equity (-23.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is Enlivex Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ENLV's short term assets ($36.6M) exceed its short term liabilities ($5.3M).

Long Term Liabilities: ENLV's short term assets ($36.6M) exceed its long term liabilities ($256.0K).


Debt to Equity History and Analysis

Debt Level: ENLV is debt free.

Reducing Debt: ENLV has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENLV has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ENLV has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 33.2% each year


Next Steps

Dividend

What is Enlivex Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENLV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENLV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENLV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENLV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENLV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average board tenure


CEO

Oren Hershkovitz (42yo)

0.58

Tenure

US$295,600

Compensation

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi ...


CEO Compensation Analysis

Compensation vs Market: Oren's total compensation ($USD295.60K) is below average for companies of similar size in the US market ($USD577.87K).

Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Shai Novik
Executive Chairman6.42yrsUS$536.00k3.78% $2.7m
Abraham Havron
Independent Director6.42yrsno data3.24% $2.3m
Michel Habib
Independent Director3.42yrsno datano data
Bernhard Kirschbaum
Independent Director2.42yrsno datano data
Baruch Halpert
Director3.42yrsUS$60.00k0.43% $308.9k
Gili Hart
Independent Director6.42yrsno data0.21% $152.1k
Sangwoo Lee
Independent Director3.42yrsno datano data
Mohamad Mohty
Clinical advisorno datano datano data
Hyun Lee
Independent Director3.42yrsno datano data
Paul Martin
Clinical advisorno datano datano data

3.4yrs

Average Tenure

52.5yo

Average Age

Experienced Board: ENLV's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.8%.


Top Shareholders

Company Information

Enlivex Therapeutics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Enlivex Therapeutics Ltd.
  • Ticker: ENLV
  • Exchange: NasdaqCM
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$71.168m
  • Shares outstanding: 13.43m
  • Website: https://www.enlivex.com

Number of Employees


Location

  • Enlivex Therapeutics Ltd.
  • 14 Einstein Street
  • Nes Ziona
  • 7403618
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENLVNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDMar 2019
1BTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2019
ENLVTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSMar 2019

Biography

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 06:13
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.